Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2000
10/03/2000US6127351 Method for the administration of amifostine and related compounds
10/03/2000US6127349 For increasing the water solubility and bioavailability of pharmaceutical agents by conjugation to phospholipids
10/03/2000US6127348 Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
10/03/2000US6127346 For the treatment of viruses
10/03/2000US6127345 Utilizing glucose 6-phosphate dehydrogenase gene polypeptide for the protection against infection, particularly bacterial infections
10/03/2000US6127332 Muteins of IFN-β
10/03/2000US6127147 Sensor histidine kinase of Staphylococcus Aureus
10/03/2000US6126932 Insoluble polymer bearing pendant side chains, said side chains each terminating with the 1-(3-(1-pyrrolidinyl)-propyl)-3-ethylcarbodiimide moiety.
10/03/2000US6126917 Epidermal growth factor receptor binding compounds for positron emission tomography
09/2000
09/28/2000WO2000056918A1 Method for screening cysteine protease inhibitor
09/28/2000WO2000056910A1 Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites
09/28/2000WO2000056899A1 Dsp-2 dual-specificity map kinase phosphatase
09/28/2000WO2000056891A2 Human transmembrane proteins
09/28/2000WO2000056889A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same
09/28/2000WO2000056886A1 MATERIALS AND METHODS RELATING TO MODULATION OF p66 EXPRESSION
09/28/2000WO2000056883A1 49 human secreted proteins
09/28/2000WO2000056881A1 48 human secreted proteins
09/28/2000WO2000056880A1 50 human secreted proteins
09/28/2000WO2000056866A2 Akt-3 nucleic acids, polypeptides, and uses thereof
09/28/2000WO2000056864A2 Methods for altering substrate specificity of phosphoinositide-dependent-protein kinase 1 (pdk1)
09/28/2000WO2000056772A1 Human antibodies that bind human il-12 and methods for producing
09/28/2000WO2000056767A1 46 human secreted proteins
09/28/2000WO2000056765A1 48 human secreted proteins
09/28/2000WO2000056760A1 Phenylalanine derivatives
09/28/2000WO2000056755A1 49 human secreted proteins
09/28/2000WO2000056751A1 50 human secreted proteins
09/28/2000WO2000056748A1 Xylo-lna analogues
09/28/2000WO2000056743A1 Pharmaceutical compositions comprising metal complexes
09/28/2000WO2000056742A1 Organic-arsenic compounds
09/28/2000WO2000056738A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
09/28/2000WO2000056737A2 Calanolides for inhibiting btk
09/28/2000WO2000056729A1 Chemokine recpetor binding heterocyclic compounds
09/28/2000WO2000056728A1 Tetrahydropyran derivatives and their use as therapeutic agents
09/28/2000WO2000056727A1 Tetrahydropyran derivatives and their use as therapeutic agents
09/28/2000WO2000056719A1 FUSED PYRIDOPYRIDAZINE INHIBITORS OF cGMP PHOSPHODIESTERASE
09/28/2000WO2000056718A1 Imidazole compounds
09/28/2000WO2000056712A1 Sulfonamide derivatives as 5-ht7 receptor antagonists
09/28/2000WO2000056711A1 Tricyclic indole-2-carboxylic acid compound used as nmda receptor antagonist
09/28/2000WO2000056710A1 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors
09/28/2000WO2000056709A1 Indolinone compounds as kinase inhibitors
09/28/2000WO2000056704A1 Hydroxamic and carboxylic acid derivatives
09/28/2000WO2000056702A1 Resorcinol derivatives
09/28/2000WO2000056681A1 Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction
09/28/2000WO2000056464A1 Atomising nozzle
09/28/2000WO2000056403A1 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS
09/28/2000WO2000056348A1 Inflammatory mediation obtained from atractylodes lancea
09/28/2000WO2000056345A2 Methods for limiting scar and adhesion formation
09/28/2000WO2000056341A1 Chemical compounds and their uses
09/28/2000WO2000056338A1 Quinazoline formulations and therapeutic use thereof
09/28/2000WO2000056337A1 Agents for relieving side effects
09/28/2000WO2000056335A1 Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
09/28/2000WO2000056331A1 Inhibitors of impdh enzyme
09/28/2000WO2000056324A1 The use of certain affinity nmda antagonists as antidepressants
09/28/2000WO2000056312A1 Treatment of pulmonary hypertension
09/28/2000WO2000056301A2 Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
09/28/2000WO2000056297A2 Pharmaceutical compositions comprising dipeptidy peptidase iv inhibitors for the promotion of growth
09/28/2000WO2000056296A2 Compositions for improving fertility
09/28/2000WO2000056294A2 Carnitine supplemented diet to prevent sudden death syndrome in broiler breeder type poultry
09/28/2000WO2000056279A1 Resorcinol composition
09/28/2000WO2000056153A1 Oral low dose butyrate compositions
09/28/2000WO2000056145A1 Organ arrest, protection and preservation
09/28/2000WO2000043392A3 Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments
09/28/2000WO2000041740A3 Particles for oral delivery of peptides and proteins
09/28/2000WO2000041545A3 Regulators of the pct or smoothened pathway, compositions and uses related thereto
09/28/2000WO2000041497A3 Use of apoptosis inducing agents in the treatment of (auto)immune diseases
09/28/2000WO2000040693A3 Expression of secreted human alpha-fetoprotein in transgenic animals
09/28/2000WO2000035428A3 Tricyclic nitrogen heterocycles as pde iv inhibitors
09/28/2000WO2000033839B1 Non-peptide antagonists of glp-1 receptor and methods of use
09/28/2000WO2000024396A9 Treatment of disorders of the outer retina
09/28/2000WO2000023114A3 Polymer conjugates of interferon beta- 1a and their uses
09/28/2000WO2000022142A3 Cell signaling polypeptides and nucleic acids
09/28/2000WO2000021559A3 Blocking factor b to treat complement-mediated immune disease
09/28/2000WO2000020576A3 Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein
09/28/2000WO2000003981A3 Preparation of (s)-2-amino-6,6-dimethoxyhexanoic acid methyl ester via novel dioxolanes
09/28/2000WO2000000483A3 Tubulin binding compounds (cobra)
09/28/2000WO1999067417A3 Fitness assay and associated methods
09/28/2000DE19913692A1 Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen Mechanically stable pharmaceutical dosage forms containing liquid or semisolid surface-active substances
09/28/2000CA2855415A1 Phenylalanine derivatives
09/28/2000CA2669512A1 Human antibodies that bind human il-12 and methods for producing
09/28/2000CA2368733A1 Phenylalanine derivatives
09/28/2000CA2368229A1 50 human secreted proteins
09/28/2000CA2368223A1 48 human secreted proteins
09/28/2000CA2368210A1 50 human secreted proteins
09/28/2000CA2368187A1 Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
09/28/2000CA2368047A1 Chemokine receptor binding heterocyclic compounds
09/28/2000CA2368041A1 Indolinone compounds as kinase inhibitors
09/28/2000CA2368023A1 Fused pyridopyridazine inhibitors of cgmp phosphodiesterase
09/28/2000CA2367985A1 Tetrahydropyran derivatives and their use as therapeutic agents
09/28/2000CA2367963A1 Hydroxamic and carboxylic acid derivatives
09/28/2000CA2367866A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
09/28/2000CA2367857A1 Thiourea and urea liquid-phase combinatorial libraries: synthesis and apoptosis induction
09/28/2000CA2367699A1 Inflammatory mediation obtained from atractylodes lancea
09/28/2000CA2367504A1 A screening method for a cysteine protease inhibitor
09/28/2000CA2367488A1 Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites
09/28/2000CA2367464A1 Materials and methods relating to modulation of p66 expression
09/28/2000CA2367282A1 Pharmaceutical compositions comprising metal complexes
09/28/2000CA2367112A1 Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
09/28/2000CA2367015A1 Methods of treating tardive dyskinesia and other movement disorders
09/28/2000CA2366998A1 Quinazoline formulations and therapeutic use thereof
09/28/2000CA2366926A1 Pharmaceutical compositions comprising dipeptidy peptidase iv inhibitors for the promotion of growth
1 ... 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 ... 1564